Trends in Drug Discovery Outsourcing: A Perspective – BSA bureau (press release)
By raymumme
Seven drugs of the current top-10 best selling drugs are biologics, the penetration of biologic drugs is expected to reach 30% by 2020 of the global pharmaceutical market and some of the key modalities include monoclonal antibodies, recombinant proteins, peptides, cell and gene therapy products.
Dr Subir Basak Chief Business Officer, GVK Biosciences
Over the last two decades, the Pharmaceutical industry has seen a radical change. The unprecedented downsizing of the internal discovery of big pharmaceuticals, patent expiration, shift towards biologics have seen a surge in the externalization and outsourcing activities. As the industry is looking for new sources of discovery and innovation with limited resources, there is a growing preference to move towards externalization and willingness to embrace the concept of outsourcing.
Seven drugs of the current top- 10 best selling drugs are biologics, the penetration of biologic drugs is expected to reach 30% by 2020 of the global pharmaceutical market and some of the key modalities include monoclonal antibodies, recombinant proteins, peptides, cell and gene therapy products. Global R&D spend in the biopharmaceutical industry is estimated to be $194 billion in 2016 and according to industry experts, 75-80% of the expenses can be outsourced. However, current penetration rate is around 58% which presents a huge opportunity for the CROs to tap the Trends in Drug Discovery Outsourcing: A Perspective market. The global pharmaceutical outsourcing market was estimated to be $113.7 billion in 2016 and out of which 49% is accounted for CROs. Among the $55.7 billion CRO market, 31.2% accounts for discovery-based service i.e. $17.4 billion in 2016 and the remaining 68.8% accounts for Preclinical and clinical services.
Biology related services segment is a high growth area with huge potential and expected to grow faster at a CAGR of 17.2% compared to the small molecules segment due to increase in budget allocations for R&D by biopharmaceutical companies.
The drug discovery CRO industry is witnessing increased consolidation. Many Asia-based companies are increasing their foothold in Europe and North America. GVK BIO, a Contract Research & Development Organization (CRDO) from India has taken over Aragen Bioscience. Aragen has early stage discovery biologics capabilities and played a leading role in oncology and fibrosis based animal models for preclinical biotechs in bay area. Similarly, ChemPartner established research facility in South San Francisco. Also, WuXi AppTec acquired HD Biosciences (HDB), a biology focused preclinical drug discovery CRO.
Advancement in drug discovery technologies such as iPS cells, automated high content screening, patch clamp, gene editing and DNAencoded libraries have expedited the drug discovery process with increased efficiency. There is an increased interest in the use of DNAencoded libraries (small molecules tagged with DNAs) by major pharma companies.Majority of the companies offering DNA-encoded library services are from US (DiCE, X-Chem, Ensemble therapeutics) and Europe (Nuevolution, Vipergen, Cominnex, Philochem). Thereseems to be very little competition in APAC. This trend should push some of the CROs from APAC region to acquire companies with proprietary technology in DNA-encoded libraries or to build capabilities and this seems likely to be a focus point for majority of the CROs especially from APAC.
Evolving business models including risk-based and insourcing are facilitating better collaboration between pharmaceutical companies and CROs. Some of the companies established a new business model known as insourcing which is a new sourcing for pharma where CROs work on-site at customer location in an integrated fashion. This new model provides outstanding performance with efficient cost and time.
CROs should build capabilities to differentiate in the area of Target Identification/Target Validation on how to use human disease pathology knowledge/primary tissues from humans clubbed with Omics knowledge to further validate the concepts. As most of the CROs propose targets from literature and sponsor companies consider it as risky option to invest in such projects without substantial evidences. As a de-risking strategy some CROs are investing internally and validating the concept by siRNA, knockdown approaches and take the concept to a level-up and then approach the sponsors companies who are working in similar area. This approach would increase the sponsor confidence in the CRO program.
There is a huge demand for the novel therapeutics addressing the unmet needs, for example, there are no FDA approved drugs or any therapies for NASH treatment and there is a tremendous opportunity for CROs to work on novel targets, preclinical models and biomarker to come-up with some early stage assets for partnering. Owing to market attractiveness, there is funding provided by venture capitalists to promising players, while some investors are even launching new companies to specifically work on NASH projects. For instance in February 2017, Versant Ventures formed Jecure Therapeutics through $20 million investment for NASH program development. Similarly, Third Rock Ventures formed Pliant Therapeutics with $45 million investment for TGF- signaling based NASH treatment. These companies could potentially outsource majority of the work to CROs in APAC region.
Asia is emerging as a preferred destination for outsourcing drug discovery activities due to the vast availability of skilled manpower, lower costs, favorable regulatory environment and quality data. In addition the local governments are focusing on development of healthcare and pharmaceutical industryby ensuring focus on high quality & compliance in terms of higher regulatory surveillance and training programs. Japan being the second largest pharmaceutical market in the world provides huge opportunity for CROs from APAC. Chinese and Indian pharmaceutical markets are one of the fastest growing in the world and are considered to be the preferred locations for drug discovery outsourcing primarily because of the end-to-end technological capabilities developed over several years. Asian CROs have strong capabilities in biologics research services and built new technology platforms for high-throughput screening, genomics and proteomics research panel screening, enzymatic, and binding assays. They are also well equipped with transgenic and disease animal models that have been developed for target validation, efficacy, and safety studies, thereby providing clients with end-to-end services. Indian CROs typically focus more on new chemical entities and offer integrated discovery services at much lower cost.
Therapeutic area gap analysis research indicates that the key contract research organizations in Asia pacific region are majorly focusing on Oncology, metabolic diseases, Inflammation and CNS. However, majority of Pharma companies in addition to the above therapeutic areas are also focusing on other areas like cardiovascular, immunology, infectious diseases. Since there is a high gap in these therapeutic areas, the CROs should increase their focus in order to tap the opportunity.
Growth in biologics research and orphan drugs, innovative technological platforms and evolving business models encourage pharma and biotech companies to outsource. Even though, big pharma is moving towards research institutions and academia to accelerate knowledge and leverage innovation and technology platforms, they lack the infrastructure to move the drugs from early stages of drug discovery. These factors are expected to enhance drug discovery outsourcing market in APAC region for the coming years.
Go here to see the original:
Trends in Drug Discovery Outsourcing: A Perspective - BSA bureau (press release)
- 001 Ying Liu discusses IPS cell therapy for ALS [Last Updated On: August 6th, 2011] [Originally Added On: August 6th, 2011]
- 002 Jeanne Loring talks about stem cells, part 2 [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- 003 Embryonic Stem Cells From Skin: Making Old Cells Young [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- 004 IPs cells Part3 [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- 005 IPs cells Part 2 [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- 006 A Century of Stem Cells - Johns Hopkins Medicine [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- 007 Stem Cell Implications for ALS (Amyotrophic Lateral Sclerosis) [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- 008 Myelin Repair Foundation on Stem Cell Research [Last Updated On: September 9th, 2011] [Originally Added On: September 9th, 2011]
- 009 IPs Cells Part 4 [Last Updated On: September 11th, 2011] [Originally Added On: September 11th, 2011]
- 010 National Medical Report [Last Updated On: September 13th, 2011] [Originally Added On: September 13th, 2011]
- 011 IPs cells Part 1 [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- 012 iPS Stem Cell-Based Treatment of Epidermolysis Bullosa [Last Updated On: September 16th, 2011] [Originally Added On: September 16th, 2011]
- 013 Jeanne Loring talks about stem cells, part 1 [Last Updated On: September 16th, 2011] [Originally Added On: September 16th, 2011]
- 014 Kristopher Nazor 2 [Last Updated On: September 16th, 2011] [Originally Added On: September 16th, 2011]
- 015 Andalusian Stem Cell Bank [Last Updated On: September 19th, 2011] [Originally Added On: September 19th, 2011]
- 016 Cellular Reprogramming Stem Cell Domain Name For Sale! - CellularReprogramming.com [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- 017 Dr. Oz to Oprah and Michael J Fox: "The stem cell debate is dead." [Last Updated On: September 22nd, 2011] [Originally Added On: September 22nd, 2011]
- 018 Manning, Owens Try Stem Cell Therapy [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- 019 Jeanne Loring talks about stem cells, part 3 [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- 020 Epidermolysis Bullosa: Corrected iPS Stem Cell-Based Therapy - Video [Last Updated On: October 13th, 2011] [Originally Added On: October 13th, 2011]
- 021 Introduction to Stem Cells - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- 022 Parkinson's Disease: Progress and Promise in Stem Cell Research - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- 023 stem cell research - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- 024 Ian Wilmut discusses stem cell and direct cellular transformation therapy - Video [Last Updated On: December 8th, 2011] [Originally Added On: December 8th, 2011]
- 025 Jeff Bluestone: Immune rejection of stem cell transplants - Video [Last Updated On: December 8th, 2011] [Originally Added On: December 8th, 2011]
- 026 Advances in Stem Cell Research: Shinya Yamanaka - Video [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 027 2011 Summit: Stem Cells, Reprogramming and Personalized Medicine, Rudolf Jaenisch, MD - Video [Last Updated On: December 14th, 2011] [Originally Added On: December 14th, 2011]
- 028 Parkinson's Disease: Advancing Stem Cell Therapies - 2011 CIRM Grantee Meeting - Video [Last Updated On: January 20th, 2012] [Originally Added On: January 20th, 2012]
- 029 Professor Alan Trounson - World focus on stem cell research - Video [Last Updated On: January 27th, 2012] [Originally Added On: January 27th, 2012]
- 030 Stanford scientists turn skin cells into neural precusors, bypassing stem-cell stage [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- 031 Researchers turn skin cells into neural precusors, bypassing stem-cell stage [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- 032 “Wide-ranging applications for pluripotent stem cells” [Last Updated On: February 2nd, 2012] [Originally Added On: February 2nd, 2012]
- 033 Radiation treatment transforms breast cancer cells into cancer stem cells [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 034 Radiation Treatment Generates Cancer Stem Cells from Less Aggressive Breast Cancer Cells [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 035 Radiation treatment generates cancer stem cells from less aggressive breast cancer cells, study suggests [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 036 Life Technologies Scientist Uma Lakshmipathy presents, "Solving Challenges in the Generation of Induced Pluripotent ... [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 037 Radiation therapy transforms breast cancer cells into cancer stem cells [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 038 Research and Markets: Primary and Stem Cells: Gene Transfer Technologies and Applications [Last Updated On: February 15th, 2012] [Originally Added On: February 15th, 2012]
- 039 Horizon in new super-cell elite [Last Updated On: February 16th, 2012] [Originally Added On: February 16th, 2012]
- 040 Presentations at the Society of Toxicology Annual Meeting Demonstrate Superior Predictivity of Cellular Dynamics ... [Last Updated On: March 8th, 2012] [Originally Added On: March 8th, 2012]
- 041 New approach to treating type 1 diabetes? Transforming gut cells into insulin factories [Last Updated On: March 12th, 2012] [Originally Added On: March 12th, 2012]
- 042 Gut cells transformed into insulin factories 'could help to treat type I diabetes' [Last Updated On: March 12th, 2012] [Originally Added On: March 12th, 2012]
- 043 A new approach to treating type I diabetes? Gut cells transformed into insulin factories [Last Updated On: March 12th, 2012] [Originally Added On: March 12th, 2012]
- 044 Columbia Researchers Find Potential Role for Gut Cells in Treating Type I Diabetes [Last Updated On: March 12th, 2012] [Originally Added On: March 12th, 2012]
- 045 Study demonstrates cells can acquire new functions through transcriptional regulatory network [Last Updated On: March 14th, 2012] [Originally Added On: March 14th, 2012]
- 046 Gut Cells Turned To Insulin Factories - New Type l Diabetes Treatment [Last Updated On: March 14th, 2012] [Originally Added On: March 14th, 2012]
- 047 Cellular Dynamics Expands Distribution Agreement with iPS Academia Japan, Inc. to Include Distribution of iCell ... [Last Updated On: March 28th, 2012] [Originally Added On: March 28th, 2012]
- 048 :: 20, Apr 2012 :: IBN DISCOVERS HUMAN NEURAL STEM CELLS WITH TUMOR TARGETING ABILITY – A PROMISING DISCOVERY FOR ... [Last Updated On: April 22nd, 2012] [Originally Added On: April 22nd, 2012]
- 049 Human neural stem cells with tumor targeting ability discovered [Last Updated On: April 22nd, 2012] [Originally Added On: April 22nd, 2012]
- 050 IBN Discovers Human Neural Stem Cells, Promising Discovery For Breast Cancer Therapy [Last Updated On: April 22nd, 2012] [Originally Added On: April 22nd, 2012]
- 051 IBN Discovers Human Neural Stem Cells with Tumor Targeting Ability - A Promising Discovery for Breast Cancer Therapy [Last Updated On: April 22nd, 2012] [Originally Added On: April 22nd, 2012]
- 052 VistaGen Secures Key U.S. Patent Covering Stem Cell Technology Methods Used to Test Drug Candidates for Liver Toxicity [Last Updated On: April 25th, 2012] [Originally Added On: April 25th, 2012]
- 053 Improved adult-derived human stem cells have fewer genetic changes than expected [Last Updated On: May 2nd, 2012] [Originally Added On: May 2nd, 2012]
- 054 Researchers restore neuron function to brains damaged by Huntington's disease [Last Updated On: May 31st, 2012] [Originally Added On: May 31st, 2012]
- 055 Cellular Dynamics Launches MyCell™ Services [Last Updated On: June 7th, 2012] [Originally Added On: June 7th, 2012]
- 056 Fate Therapeutics And BD Biosciences Launch BD™ SMC4 To Improve Cellular Reprogramming And IPS Cell Culture Applications [Last Updated On: June 12th, 2012] [Originally Added On: June 12th, 2012]
- 057 Life Technologies and Cellular Dynamics International Partner for Global Commercialization of Novel Stem Cell ... [Last Updated On: June 13th, 2012] [Originally Added On: June 13th, 2012]
- 058 LIFE Focuses on Stem Cell Research - Analyst Blog [Last Updated On: June 20th, 2012] [Originally Added On: June 20th, 2012]
- 059 International Stem Cell Corp Granted Key Patent for Liver Disease Program [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- 060 NeuroGeneration Recruits Top Scientist To Direct New Division of Biotherapeutics and Drug Discovery In La Jolla, CA [Last Updated On: October 5th, 2012] [Originally Added On: October 5th, 2012]
- 061 FRC Supports Alliance Defending Freedom, Jubilee Campaign Cert Petition to Supreme Court on Stem Cell Funding [Last Updated On: October 11th, 2012] [Originally Added On: October 11th, 2012]
- 062 10/11/2012 10:05 JAPAN Nobel Prize for Yamanaka, scientific research and ethics must go hand in hand [Last Updated On: October 11th, 2012] [Originally Added On: October 11th, 2012]
- 063 Read in [Last Updated On: October 12th, 2012] [Originally Added On: October 12th, 2012]
- 064 Induced pluripotent stem cell - Wikipedia, the free encyclopedia [Last Updated On: November 3rd, 2013] [Originally Added On: November 3rd, 2013]
- 065 What are induced pluripotent stem cells or iPS cells? - Stem Cells ... [Last Updated On: November 3rd, 2013] [Originally Added On: November 3rd, 2013]
- 066 Stem Cell Definitions | California's Stem Cell Agency [Last Updated On: November 3rd, 2013] [Originally Added On: November 3rd, 2013]
- 067 iPSCTherapy.com: Induced Pluripotent Stem Cell therapy Information ... [Last Updated On: November 8th, 2013] [Originally Added On: November 8th, 2013]
- 068 Human muscle stem cell therapy gets help from zebrafish [Last Updated On: November 8th, 2013] [Originally Added On: November 8th, 2013]
- 069 Induced pluripotent stem cell therapy - Wikipedia, the free ... [Last Updated On: November 8th, 2013] [Originally Added On: November 8th, 2013]
- 070 IPS Cell Therapy - Genetherapy [Last Updated On: November 8th, 2013] [Originally Added On: November 8th, 2013]
- 071 MD Supervised Stem Cell Therapy [Last Updated On: November 9th, 2013] [Originally Added On: November 9th, 2013]
- 072 Stem Cell Therapy for Neuromuscular Diseases | InTechOpen [Last Updated On: November 23rd, 2013] [Originally Added On: November 23rd, 2013]
- 073 Combining Stem Cell Therapy with Gene Therapy | Boston ... [Last Updated On: November 25th, 2013] [Originally Added On: November 25th, 2013]
- 074 Biomanufacturing center takes central role in developing stem ... [Last Updated On: December 4th, 2013] [Originally Added On: December 4th, 2013]
- 075 Stem Cell Quick Reference - Learn Genetics [Last Updated On: December 6th, 2013] [Originally Added On: December 6th, 2013]
- 076 Induced Pluripotent Stem Cells (iPS) from Human Skin: Probable ... [Last Updated On: December 6th, 2013] [Originally Added On: December 6th, 2013]
- 077 'Something positive for humankind': Girls lend cells to genetic study [Last Updated On: December 13th, 2013] [Originally Added On: December 13th, 2013]
- 078 Stem cell science: Can two girls help change the face of medicine? [Last Updated On: December 13th, 2013] [Originally Added On: December 13th, 2013]
- 079 Okyanos Heart Institute CEO Matt Feshbach Congratulates Japan’s Legislators On Stem Cell Bill And Global Regulatory ... [Last Updated On: December 13th, 2013] [Originally Added On: December 13th, 2013]
- 080 Stem cells for Parkinson's getting ready for clinic [Last Updated On: December 13th, 2013] [Originally Added On: December 13th, 2013]
